<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009876</url>
  </required_header>
  <id_info>
    <org_study_id>HM-RE-2017-01</org_study_id>
    <nct_id>NCT04009876</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer</brief_title>
  <official_title>Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy NALIRINOX (5-FU/LV + Oxaliplatin + Nal-IRI) Followed by Chemoradiotherapy in Patients With Rectal Cancer in a Watch-and-wait Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de investigación HM</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntax for Science, S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de investigación HM</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II&#xD;
      clinical trial to determine the efficacy and clinical complete response rate in patients with&#xD;
      rectal cancer and tumor preoperative evaluation after NAC (Neoadjuvant Chemotherapy) with&#xD;
      NALIRINOX (5-FU [fluorouracil)/LV [Leucovorin calcium] + oxaliplatin + nal-IRI [Liposomal&#xD;
      Irinotecan]) and chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cCR (clinical complete response) rate in LARC ( locally advanced rectal cancer ) patients treated with chemo - chemoradiation.</measure>
    <time_frame>expected 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that follow the &quot;watch-and-wait&quot; surveillance protocol</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall toxicity</measure>
    <time_frame>Through the study completion (estimated to be 15 months)</time_frame>
    <description>acute and late toxicity of neoadjuvant treatment (chemo and chemoradiotherapy) according to the Common Toxicity Criteria (CTC) for adverse events (AE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Locally Advanced Rectal Cancer (LARC)</condition>
  <arm_group>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks) and &quot;watch-and-wait&quot; surveillance protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nal-IRI</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical resection</intervention_name>
    <description>Surgical resection of the tumour</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Watch-and-wait</intervention_name>
    <description>No surgery approach</description>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU/LV</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)</description>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_label>Chemotherapy + Watch-and-wait</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or females, aged ≥ 18 years.&#xD;
&#xD;
          -  Agree to participate and sign voluntary written ICF (Informed Consent Form) before any&#xD;
             study specific procedure.&#xD;
&#xD;
          -  Patients with confirmed histopathological diagnosis of rectal cancer.&#xD;
&#xD;
          -  Patients with locally advanced rectal cancer T3-T4N0M0 or TxN+M0 and selected T2N0M0&#xD;
             candidates to watch &amp; wait program.&#xD;
&#xD;
          -  Patients considered for neoadjuvant treatment according to usual clinical practice may&#xD;
             also be potential candidates.&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Grou)vperformance status 0 or 1.&#xD;
&#xD;
          -  Patients who can receive radiotherapy and chemotherapy.&#xD;
&#xD;
          -  No prior or concurrent malignant disease unless in complete remission for more than&#xD;
             three years, except for adequately treated in situ carcinoma of the cervix, basal or&#xD;
             squamous skin cell carcinoma or in situ transitional bladder cell carcinoma.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum pregnancy test&#xD;
             before study entry. Both women and men must agree to use a highly effective&#xD;
             contraceptive measure throughout the treatment period and for six months after&#xD;
             discontinuation of treatment.&#xD;
&#xD;
          -  Adequate hematologic function: hemoglobin ≥ 9g/dL; WBC (white blood cell count ) ≥&#xD;
             4000/mm 3 ; neutrophils ≥ 1.5x10 9 /L; platelets ≥ 100x10 9 /L.&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤ 1.5xULN; ALT / AST (Alanine&#xD;
             aminotransferase / Aspartate aminotransferase) ≤ 2.5xULN (Upper Limit of Normality)&#xD;
             alkaline phosphatase ≤ 3xULN.&#xD;
&#xD;
          -  Adequate renal function: creatinine ≤ 1xULN; creatinine clearance ≥ 60ml/min.&#xD;
&#xD;
          -  No peripheral neuropathy (&lt; Grade 2)&#xD;
&#xD;
          -  No known history of dihydropyrimidine dehydrogenase deficiency (DPD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with ECOG performance status ≥ 2.&#xD;
&#xD;
          -  Stage I (T1N0M0) or stage IV (TxNxM1) AJCC (American Joint Committee on Cancer) rectal&#xD;
             cancer.&#xD;
&#xD;
          -  Any illness that the investigator considers will substantially increase the risk if&#xD;
             the patient participates in the study.&#xD;
&#xD;
          -  Pregnant or breast-feeding woman.&#xD;
&#xD;
          -  Chronically active hepatitis B or C virus infection.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  History, within last year, or presence of unstable angina, myocardial infarction,&#xD;
             symptomatic congestive heart failure or asymptomatic left ventricular ejection&#xD;
             fraction &lt; 50% (assessed by multiple-gated acquisition scan or equivalent by&#xD;
             ultrasound) or clinically significant valvular heart disease.&#xD;
&#xD;
          -  Peripheral neuropathy (&gt; Grade 1)&#xD;
&#xD;
          -  Known history of dihydropyrimidine dehydrogenase deficiency (DPD)&#xD;
&#xD;
          -  Known or suspected reactions to any component of the study medication (5-FU,&#xD;
             leucovorin, irinotecan or oxaliplatin) or to components of similar chemical or&#xD;
             biologic composition.&#xD;
&#xD;
          -  Any phycological, familiar, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol or follow-up schedule.&#xD;
&#xD;
          -  Concurrent participation in any other clinical trial likely to interfere with the&#xD;
             therapeutic schedule.&#xD;
&#xD;
          -  Patients that had received any previous treatment for their rectal cancer (surgery,&#xD;
             chemotherapy or radiotherapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Cubillo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Sanchinarro</city>
        <state>Madrid</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

